KINLYTIC (UROKINASE FOR INJECTION) 250000 UNIT
UROKINASE : 250000 UNIT · DIN 00749702 · MICROBIX BIOSYSTEMS INC
Health Canada status: CANCELLED POST MARKET
What is KINLYTIC (UROKINASE FOR INJECTION)?
KINLYTIC (UROKINASE FOR INJECTION) 250000 UNIT contains UROKINASE : 250000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 00749702, held by MICROBIX BIOSYSTEMS INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 28-Oct-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KINLYTIC (UROKINASE FOR INJECTION) used for?
Lysis of acute massive pulmonary emboli; coronary artery thrombosis; peripheral arterial and graft thromboembolic occlusion; restoration of patency to intravenous catheters.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00749702 |
|---|---|
| Brand name | KINLYTIC (UROKINASE FOR INJECTION) |
| Generic / active ingredient | UROKINASE : 250000 UNIT |
| Manufacturer | MICROBIX BIOSYSTEMS INC |
| Strength | 250000 UNIT |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B01AD04 UROKINASE |
| AHFS class | 20:12.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Oct-2009 |
| Original market date | 1988-12-31 00:00:00 |
How is it administered?
Pulmonary Embolism: 4,400 IU/kg priming dose over 10 min, then 4,400 IU/kg/hr for 12 hours. Also used for coronary artery thrombi, peripheral arterial occlusion, and I.V. catheter clearance.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store powder at 2° - 30°C. Reconstitute immediately before use; contains no preservatives.
How is it supplied?
Vials containing 250,000 IU or 1,000,000 IU of urokinase. Also available as KINLYTIC OPEN-CATH in 5,000 IU or 9,000 IU vials.
Contraindications
Active internal bleeding, history of CVA, recent intracranial/intraspinal surgery or trauma, intracranial neoplasm, aneurysm, bleeding diathesis, severe uncontrolled hypertension, aortic dissection.
Warnings and precautions
Potential for transmission of infectious agents (human source material). High risk of bleeding; avoid invasive procedures. Monitor for cholesterol embolization and reperfusion arrhythmias.
What can be used instead?
Other Canadian products sharing ATC code B01AD04 UROKINASE. 0 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| KINLYTIC OPEN-CATH | 5000 UNIT | POWDER FOR SOLUTION | MICROBIX BIOSYSTEMS INC | CANCELLED POST MARKET | DIN 00886777 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.